Mutations in bone cells can drive leukemia in neighboring stem cells

Certain DNA mutations in bone cells that support blood development can drive leukemia formation in nearby blood stem cells, researchers from Winship Cancer Institute, Emory University and Children&#39

Updated on: November 02,2023 5

Mutations in bone cells can drive leukemia in neighboring stem cells

Certain DNA mutations in bone cells that support blood development can drive leukemia formation in nearby blood stem cells, researchers from Winship Cancer Institute, Emory University and Children&#39

Updated on:November 02,2023 5

Addition of maintenance olaparib slows advanced ovarian cancer

(HealthDay)—Compared with placebo, the addition of olaparib to maintenance therapy with bevacizumab is associated with a significant progression-free survival benefit for patients with advanced ovaria

Updated on: December 22,2023 13

Addition of maintenance olaparib slows advanced ovarian cancer

(HealthDay)—Compared with placebo, the addition of olaparib to maintenance therapy with bevacizumab is associated with a significant progression-free survival benefit for patients with advanced ovaria

Updated on:December 22,2023 13

Progression-free survival increased with zanubrutinib in leukemia

by Elana Gotkine HealthDay ReporterProgression-free survival is significantly longer with zanubrutinib than ibrutinib among patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or s

Updated on: December 19,2023 12

Progression-free survival increased with zanubrutinib in leukemia

by Elana Gotkine HealthDay ReporterProgression-free survival is significantly longer with zanubrutinib than ibrutinib among patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or s

Updated on:December 19,2023 12

Cilta-Cel Leads to High PFS Rates in Patients With Multiple Myeloma and Poor Prognostic Features

September 30, 2023Courtney FlahertyPatients with multiple myeloma exhibiting poor prognostic features, such as high-risk cytogenetics, soft-tissue plasmacytoma, ISS stage III disease, and triple-class

Updated on: October 10,2023 265

Cilta-Cel Leads to High PFS Rates in Patients With Multiple Myeloma and Poor Prognostic Features

September 30, 2023Courtney FlahertyPatients with multiple myeloma exhibiting poor prognostic features, such as high-risk cytogenetics, soft-tissue plasmacytoma, ISS stage III disease, and triple-class

Updated on:October 10,2023 265

Cevidoplenib Elicits Platelet Responses in Persistent or Chronic Immune Thrombocytopenia

June 11, 2023Chris RyanThe novel SYK inhibitor cevidoplenib dosed at 400 mg twice per day led to robust platelet responses in patients with persistent or chronic primary immune thrombocytopenia who di

Updated on: October 24,2023 27

Cevidoplenib Elicits Platelet Responses in Persistent or Chronic Immune Thrombocytopenia

June 11, 2023Chris RyanThe novel SYK inhibitor cevidoplenib dosed at 400 mg twice per day led to robust platelet responses in patients with persistent or chronic primary immune thrombocytopenia who di

Updated on:October 24,2023 27

Lung Responses to Atezolizumab/Bevacizumab Linked With OS in HCC and Pulmonary Metastasis

September 20, 2023Ashling WahnerEarly lung-specific response to atezolizumab plus bevacizumab was associated with longer overall survival in patients with hepatocellular carcinoma with pulmonary metas

Updated on: October 10,2023 163

Lung Responses to Atezolizumab/Bevacizumab Linked With OS in HCC and Pulmonary Metastasis

September 20, 2023Ashling WahnerEarly lung-specific response to atezolizumab plus bevacizumab was associated with longer overall survival in patients with hepatocellular carcinoma with pulmonary metas

Updated on:October 10,2023 163

New cell-based immunotherapy offered for melanoma

by Julia Evangelou Strait,Washington University School of Medicine in St. LouisCredit: Pixabay/CC0 Public DomainSiteman Cancer Center, based at Barnes-Jewish Hospital and Washington University S

Updated on: April 02,2024 19

New cell-based immunotherapy offered for melanoma

by Julia Evangelou Strait,Washington University School of Medicine in St. LouisCredit: Pixabay/CC0 Public DomainSiteman Cancer Center, based at Barnes-Jewish Hospital and Washington University S

Updated on:April 02,2024 19

CHMP Recommends Against Renewal of Marketing Authorization for Belantamab Mafodotin in R/R Myeloma

September 18, 2023Chris RyanThe European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended against renewal of the conditional marketing authorization for belantamab maf

Updated on: October 24,2023 77

CHMP Recommends Against Renewal of Marketing Authorization for Belantamab Mafodotin in R/R Myeloma

September 18, 2023Chris RyanThe European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended against renewal of the conditional marketing authorization for belantamab maf

Updated on:October 24,2023 77

Novel tool helps differentiate between cancerous and healthy cells for AML

Spanish scientists have developed a new method to identify between cancerous and healthy cells for cases of acute myeloid leukaemia (AML).Researchers from Centre for Genomic Regulation (CRG), Spain, h

Updated on: October 31,2023 19

Novel tool helps differentiate between cancerous and healthy cells for AML

Spanish scientists have developed a new method to identify between cancerous and healthy cells for cases of acute myeloid leukaemia (AML).Researchers from Centre for Genomic Regulation (CRG), Spain, h

Updated on:October 31,2023 19

Tumor Sequencing Identifies Host Signatures Tied to Immunotherapy Response in Advanced RCC

July 14, 2023Caroline SeymourHigher levels of baseline TCR clonality in peripheral blood mononuclear cells (PBMCs) and baseline IgG1 fraction in PBMCs and tumor tissue were identified in an institutio

Updated on: October 24,2023 49

Tumor Sequencing Identifies Host Signatures Tied to Immunotherapy Response in Advanced RCC

July 14, 2023Caroline SeymourHigher levels of baseline TCR clonality in peripheral blood mononuclear cells (PBMCs) and baseline IgG1 fraction in PBMCs and tumor tissue were identified in an institutio

Updated on:October 24,2023 49

New epigenetic markers for prostate cancer discovered

byGarvan Institute of Medical ResearchHistopathological image of a high grade prostate cancer. Credit: Prof James KenchNew epigenetic biomarkers to predict more aggressive forms of prostate canc

Updated on: December 21,2023 10

New epigenetic markers for prostate cancer discovered

byGarvan Institute of Medical ResearchHistopathological image of a high grade prostate cancer. Credit: Prof James KenchNew epigenetic biomarkers to predict more aggressive forms of prostate canc

Updated on:December 21,2023 10

Targeting menin induces responses in acute leukemias with KMT2A rearrangements or NPM1 mutations

byUniversity of Texas M. D. Anderson Cancer CenterBone marrow aspirate showing acute myeloid leukemia. Several blasts have Auer rods. Credit: WikipediaResearchers from The University of Texas MD

Updated on: December 19,2023 12

Targeting menin induces responses in acute leukemias with KMT2A rearrangements or NPM1 mutations

byUniversity of Texas M. D. Anderson Cancer CenterBone marrow aspirate showing acute myeloid leukemia. Several blasts have Auer rods. Credit: WikipediaResearchers from The University of Texas MD

Updated on:December 19,2023 12